BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260623
DTEND;VALUE=DATE:20260626
DTSTAMP:20260514T232713
CREATED:20260313T132352Z
LAST-MODIFIED:20260313T132352Z
UID:43137-1782172800-1782431999@www.pharmajournalist.com
SUMMARY:8th T-Cell Engager Therapeutics Summit
DESCRIPTION:8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting \nThe T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality\, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic\, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy. \nOver the past year\, the landscape has seen a sharp rise in investment\, strategic alliances\, and high‑value partnerships. Landmark collaborations\, including BMS × JanuX Therapeutics\, Candid Therapeutics × WuXi Biologics\, and AbbVie × EvolveImmune\, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease. \nNow moving from Boston to San Diego for 2026\, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing\, optimizing\, and translating TCEs. This case‑study‑driven forum equips engineering\, discovery\, R&D\, translational\, and clinical development teams with the actionable insights needed to design safer\, more potent\, durable\, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications. \nIf accelerating your TCE pipeline is a priority\, this is the meeting you cannot afford to miss. \nWhat’s New in 2026? \nTwo Brand‑New Parallel Tracks\nTailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation\, enabling deep dives aligned to your role and pipeline stage. \nFresh Clinical Insights in Combination & Precision Immunotherapy\nHear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration\, co‑stimulation pairings\, and combination‑ready TCE design for deeper\, more durable responses in solid tumors. \nExplore the Full Event Guide \n120+ Industry Attendees\n28+ Expert Speakers\n8+ Hours of Networking\n6 Deep‑Dive Workshops\n1 Modality at the Center\nThe Only Forum Advancing TCEs Across Oncology & Autoimmune Disease \nView the Full Program – See all sessions\, speakers\, and workshops: https://ter.li/fulua0
URL:https://www.pharmajournalist.com/event/8th-t-cell-engager-therapeutics-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR